WO2020189749A1 - 改変アデノウイルス及びこれを含む医薬 - Google Patents
改変アデノウイルス及びこれを含む医薬 Download PDFInfo
- Publication number
- WO2020189749A1 WO2020189749A1 PCT/JP2020/012196 JP2020012196W WO2020189749A1 WO 2020189749 A1 WO2020189749 A1 WO 2020189749A1 JP 2020012196 W JP2020012196 W JP 2020012196W WO 2020189749 A1 WO2020189749 A1 WO 2020189749A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gene
- adenovirus
- modified
- modified adenovirus
- cells
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
Definitions
- the present invention relates to a modified adenovirus incorporating a gene encoding an AU-rich element, which has specific cell-killing activity against cells in which the stabilization of mRNA containing the AU-rich element is enhanced, and a drug containing the same. Regarding.
- Onyx-015 A typical example of an oncolytic virus is an adenovirus called Onyx-015, which lacks the gene encoding E1B55K (Non-Patent Document 1).
- This adenovirus is a virus that cannot express the 55 kDa protein (E1B55K) encoded by the E1B gene, and the tumor suppressor gene p53 does not function normally (including the case where it expresses the mutant p53). Or, it shows a cell-killing effect on tumor cells in which the mRNA of the late virus gene is transported to the outside of the nucleus.
- E1B55K 55 kDa protein
- p53 the tumor suppressor gene p53 does not function normally
- it shows a cell-killing effect on tumor cells in which the mRNA of the late virus gene is transported to the outside of the nucleus.
- the main purpose of the present invention is to expand the range of applicable tumors, and to stabilize mRNA containing an AU-rich element (also called AU-Rich Element, also referred to as AU-rich sequence, hereinafter referred to as ARE) in tumor cells.
- AU-rich element also called AU-Rich Element, also referred to as AU-rich sequence, hereinafter referred to as ARE
- a modified adenovirus having a gene was presented (Patent Document 1).
- ARE is a region rich in adenine (A) and uracil (U) that exists in the 3'terminal untranslated region of mRNA, and is the 3'non of mRNA transcribed from growth-related genes such as cancer genes or cytokine genes. Frequently present in the translation area.
- mRNA containing ARE hereinafter referred to as ARE-mRNA
- TTP Tristetraprolin
- Zfp36L1, Zfp36L2, AUF1, KSRP, etc. recognize and bind to ARE. ..
- the HuR protein binds to ARE, and HuR transports ARE-mRNA out of the nucleus and stabilizes it in cells under various stresses.
- HuR Since HuR is stably localized in the cytoplasm in specific cells such as tumor cells and inflammation-related cells, ARE-mRNA is constitutively stabilized by HuR in modified viruses into which ARE has been introduced. It is expected to exhibit efficacy and safety that it proliferates selectively in these cells and does not proliferate in normal cells. Ensuring efficacy and safety, especially safety, is one of the most important issues for oncolytic viruses.
- An object of the present invention is to provide a modified adenovirus having cell-killing activity against target cells and having high safety.
- the enhancer sequence having the function of increasing the expression of the E1A gene, and the viral gene essential for self-proliferation, or at a position adjacent to the 3'untranslated region.
- the modified adenovirus with a distance between 1500 bp and 4500 bp.
- the modified adenovirus according to (4) which has a modified E4orf6 gene consisting of the nucleotide sequence shown in SEQ ID NO: 1 or the nucleotide sequence encoding the same amino acid sequence as the amino acid sequence encoded by the sequence.
- the modified adenovirus according to (4) which has a modified E4orf6 gene encoding the amino acid sequence shown in SEQ ID NO: 2.
- the modified adenovirus described in. (9) The modified adenovirus according to (8), wherein the viral gene essential for self-proliferation is the E1A gene.
- a modified adenovirus having cell-killing activity against target cells and having high safety, and a drug containing this is effective against rheumatism in addition to cancer. It can be a therapeutic drug.
- E1A protein results of analysis of the expression level of E1A protein when A549 cells derived from human alveolar basal epithelial adenocarcinoma are infected with modified adenovirus AdARET-R, wild-type adenovirus wt300 or E1B55k-deficient adenovirus dl1520 are shown. It is a figure. It is a graph which shows the cell killing activity of modified adenovirus AdARET-R against BJ cell which is a normal cell, or HeLa cell derived from human cervical cancer. It is a graph which shows the cell-killing activity of modified adenovirus AdARET-R against HeLa cells or A549 cells in comparison with control adenovirus AdARET.
- the first aspect of the present invention is in the 3'untranslated region of the E1A gene, an enhancer sequence having a function of increasing the expression of the E1A gene, and a viral gene essential for self-proliferation, or in the 3'untranslated region. It relates to a modified adenovirus having an ARE introduced at an adjacent position, wherein the distance between the 5'end of the E1A gene and the end of the enhancer sequence is 1500 bp to 4500 bp.
- the modified adenovirus of the present invention has an enhancer sequence having a function of increasing the expression of the E1A gene and the E1A gene.
- adenovirus there are 51 types of adenovirus, and in the present invention, any serotype of adenovirus can be used, but it is preferable to use type 5 adenovirus, which is often used as a viral vector.
- the E1A gene is a gene encoding the E1A protein that activates transcription of the adenovirus gene, whose expression is first induced among the adenovirus genes.
- the E1A protein has a function of inducing the expression of each gene of E4, E1B, E3, E2, which is an early gene of adenovirus, and all late genes.
- an enhancer sequence (hereinafter, also simply referred to as an enhancer) is a base sequence having a function of increasing gene expression in cooperation with a promoter that controls gene expression in eukaryotic DNA.
- the enhancer is not limited as long as it has a function of increasing the expression of the E1A gene, and even a unique enhancer (E1A enhancer) existing upstream of the E1A gene of adenovirus is intracellular. It may be a heterogeneous enhancer incorporated to function in, such as a cytomegalovirus (CMV) -derived enhancer or a herpesvirus-derived enhancer.
- a particularly preferable enhancer in the present invention is an E1A enhancer (SEQ ID NO: 5) present at -192 bp to -343 bp upstream of the E1A gene of type 5 adenovirus genomic DNA.
- the enhancer may be arranged upstream or downstream of the E1A gene as long as it is arranged so as to be able to increase the expression of the E1A gene, and the base sequence of the enhancer.
- the orientation may be the same as or opposite to the transcription direction of the E1A gene.
- the lower limit of the distance between the 5'end of the E1A gene and the end of the enhancer sequence is 1500 bp, preferably 2500 bp, more preferably 2900 bp, and the upper limit is 4500 bp, preferably 3500 bp, more preferably 3200 bp.
- the distances between the 5'end of the E1A gene and the end of the enhancer sequence are, for example, 1500 bp to 4500 bp, 2500 bp to 3500 bp, and 2900 bp to 3200 bp.
- the distance between the 5'end of the E1A gene and the end of the enhancer sequence is the base at the end of the E1A gene 5'and the base at the end closer to the E1A gene of the enhancer, regardless of the arrangement and orientation of the E1A gene and the enhancer.
- the base sequence between the 5'end of the E1A gene and the end of the enhancer sequence is not particularly limited, and other genes may be present, and non-transcriptional sequences, untranslated sequences, and the like may be present. ..
- the modified adenovirus of the first aspect has an ARE introduced in the 3'untranslated region of the viral gene essential for self-proliferation or at a position adjacent to the 3'untranslated region.
- ARE stabilizes ARE-mRNA in cells in relation to proteins that promote the degradation of ARE-mRNA such as Tristetraprolin (TTP), Zfp36L1, Zfp36L2, AUF1, and KSRP, or proteins that stabilize ARE-mRNA such as HuR. Anything that has a function of controlling sex may be used.
- ARE is present in the 3'untranslated region of the c-fos gene, c-myc gene, TNF- ⁇ gene, cox-2 gene and various other genes involved in animal cell proliferation, differentiation induction or immune response. It is known that many kinds of base sequences have been reported. In the present invention, any such ARE can be used, but it is particularly preferable to use the ARE present in the human gene.
- the number of AREs to be introduced may be one or a plurality, and may be one type or a plurality of types.
- Preferred examples of ARE in the present invention are ARE (SEQ ID NO: 3) contained in the human TNF- ⁇ gene or ARE (SEQ ID NO: 6) contained in the human c-fos gene.
- the ARE in the present invention includes not only the base sequence rich in A and U in the RNA molecule but also the base sequence rich in A and T (thymine) corresponding to ARE in the DNA molecule. Therefore, “having ARE” and “containing ARE” are also used when ARE is contained in the RNA molecule and the base sequence rich in A and T corresponding to ARE is contained in the DNA molecule. ..
- "ARE is introduced” means that the genome or DNA molecule encoding the gene incorporates an A and T-rich base sequence corresponding to ARE so that ARE is contained in the mRNA molecule that is a transcript. Means.
- viral genes that are essential for self-proliferation into which ARE is introduced include E1A gene, E1B gene, E4orf6 gene, E4orf3 gene, etc., and E1A gene is preferably used.
- E1A gene is used as the viral gene into which the ARE is introduced
- the modified adenovirus of the first aspect has an E1A having an ARE introduced within the 3'untranslated region or adjacent to the 3'untranslated region.
- ARE is introduced in the 3'untranslated region of the viral gene or at a position adjacent to the 3'untranslated region.
- ARE is preferably introduced at a position from the end of the ORF stop codon of the viral gene to the beginning of the poly A sequence.
- the position adjacent to the 3'end untranslated region of the viral gene is that when mRNA is transcribed from the viral gene by RNA polymerase, ARE is contained at the 3'end of the mRNA by read through of RNA polymerase. It means a position where it can be used.
- ARE has the function of promoting the rapid degradation of mRNA containing it together with TTP and the like. Therefore, by introducing ARE into the 3'untranslated region of a viral gene essential for self-proliferation or at a position adjacent to the 3'untranslated region, the mRNA transcribed from such a viral gene is destabilized. be able to.
- the modified virus of the first aspect of the present invention contains proteins essential for proliferation encoded by ARE-mRNA in normal cells in which ARE-mRNA is rapidly degraded. Since it is not expressed, it cannot proliferate, but in cells in which the stabilization of ARE-mRNA is enhanced, the protein is stably expressed and can proliferate.
- the modified adenovirus of the first aspect can be prepared by using various genetic engineering techniques known to those skilled in the art.
- ARE is introduced into the cosmid vector pAxcwit or pAxcwit2 containing an adenovirus genomic DNA having an enhancer having a function of increasing the expression of the E1A gene, within the 3'untranslated region or adjacent to the 3'untranslated region.
- a nucleic acid fragment containing a viral gene essential for self-proliferation and an E1A gene is used, or when an E1A gene is used as a viral gene essential for self-proliferation, it is within the 3'untranslated region or the 3'untranslated region.
- a modified adenovirus DNA is constructed by incorporating a nucleic acid fragment containing the E1A gene into which ARE has been introduced at a position adjacent to the E1A gene so that the distance between the 5'end of the E1A gene and the enhancer sequence end is 1500 bp to 4500 bp. can do.
- ARE is introduced into the adenovirus DNA at a position within the 3'untranslated region or adjacent to the 3'untranslated region.
- Modified adenovirus DNA by incorporating a nucleic acid fragment containing an enhancer and an E1A gene into which ARE has been introduced and the distance between the 5'end of the E1A gene and the enhancer sequence end is 1500 bp to 4500 bp. Can be built.
- the constructed modified adenovirus DNA is transfected into a packaging cell such as HEK293 cell or HEK293T cell to translate the viral structural protein and package the viral genome to obtain the modified adenovirus of the first aspect. It can be recovered as virus particles.
- the modified adenovirus of the first aspect has an ARE introduced within the 3'untranslated region of the E1A gene, enhancer and viral gene essential for self-proliferation, or adjacent to the 3'untranslated region. And, as long as it can grow in the target cell, it may contain other genes or may lack genes that are not essential for virus growth.
- the cosmid vectors pAxcwit and pAxcwit2 exemplified above lack the E1A, E1B and E3 genes of wild-type adenovirus.
- the modified adenovirus of the present invention based on pAxcwit or pAxcwit2, it is necessary to integrate the E1A gene.
- the E1B and E3 genes are not as important for virus growth in cells with enhanced ARE-mRNA stabilization, so modified adenovirus does not need to contain these genes.
- the modified adenovirus of the first aspect has ARE introduced in the 3'untranslated region of the E1A gene, the enhancer and the viral gene essential for self-proliferation, or at a position adjacent to the 3'untranslated region.
- the position and orientation of the gene on the genome may be different from that of the wild-type adenovirus.
- a preferred example of the modified adenovirus of the first aspect is a nucleic acid fragment consisting of a partial sequence of E1A TATA box, E1A coding region, E1B promoter and E1B coding region, specifically, a base sequence of about 1627 bp from the E1B mRNA starting point.
- it is a modified adenovirus that is integrated directly under the base sequence of the E1A enhancer in the direction opposite to the direction of the base sequence of the E1A enhancer, and further, ARE is integrated in the 3'untranslated region of the E1A gene. ..
- the enhancement of cell-killing activity against tumor cells by the modified adenovirus of the present invention is presumed as follows.
- an appropriate amount of E1A-ARE mRNA is transcribed by an appropriate transcription enhancing action by the enhancer.
- the transcribed E1A-ARE mRNA is nuclear-transported, the E1A protein is stably synthesized, the adenovirus proliferates, and the tumor cells are lysed.
- the preferred modified adenovirus of the present invention described above since it does not have a complete E1B gene, it is considered that it may have properties equivalent to those of Onyx-015 and the like described above.
- Another aspect of the present invention is a modified adenovirus having an enhancer sequence having a function of increasing the expression of the E1A gene and the E1A gene and unable to express a normal E4orf6 protein, wherein the E1A gene 5'end. It relates to the modified adenovirus having a distance between the enhancer sequence and the end of the enhancer sequence of 1500 bp to 4500 bp.
- the E4orf6 protein is a gene product of E4orf6, which is one of the early genes of adenovirus, and its oncodomain on the C-terminal side (in the case of type 5 adenovirus, it corresponds to positions 204 to 294 of the E4orf6 amino acid sequence).
- E4orf6 protein and pp32 are mediated by the HuR protein, which binds directly to ARE.
- E4orf6 protein in the present invention means inability to express E4orf6 protein having the same function as wild-type E4orf6 protein, typically onco of E4orf6 protein. Expressing an E4orf6 protein that retains the ⁇ -helix structure within the oncodomain by deleting all or part of the base sequence encoding the domain, or by causing one or more mutations in the base sequence. It means that you cannot do it.
- the preferred modified adenovirus of the above embodiment has an enhancer sequence having a function of increasing the expression of the E1A gene and the E1A gene, and encodes the same amino acid sequence as the nucleotide sequence shown in SEQ ID NO: 1 or the amino acid sequence encoded by the same.
- Modified adenovirus having a modified E4orf6 gene consisting of the nucleotide sequence to be used; having an enhancer sequence having a function of increasing the expression of the E1A gene and the E1A gene, and having a modified E4orf6 gene encoding the amino acid sequence shown in SEQ ID NO: 2.
- Modified adenovirus or; a modified adenovirus having an enhancer sequence having a function of increasing the expression of the E1A gene and the E1A gene and lacking E4orf6, between the 5'end of the E1A gene and the end of the enhancer sequence.
- the modified adenovirus having a distance of 1500 bp to 4500 bp.
- modified adenovirus having a modified E4orf6 gene consisting of the nucleotide sequence shown in SEQ ID NO: 1 is an adenovirus called dl355 described in Halbert et al, J. Virology, 1985, Vol. 56, 250-257. Is.
- An example of an adenovirus lacking E4orf6 is the adenovirus called dl366 described in Halbert et al.
- the modified adenovirus of the present invention can be prepared by recombining based on dl355 or dl366 so that the distance between the 5'end of the E1A gene and the end of the enhancer sequence is 1500 bp to 4500 bp.
- a modified adenovirus having a modified E4orf6 gene encoding the amino acid sequence encoded by the base sequence shown in SEQ ID NO: 1 is also composed of a base sequence different from the base sequence shown in SEQ ID NO: 1 due to so-called codon degeneration. , Consists of one aspect of the invention.
- the modified adenovirus of the present invention can exhibit high proliferative ability and cell-killing activity in cells in which ARE-mRNA stabilization is enhanced, it is a drug for treating diseases involving such cells. It can be used. Therefore, the present invention provides, as a further embodiment, a medicament containing an adenovirus for treating a disease involving cells in which ARE-mRNA is enhanced in stabilization, including the modified virus.
- the stabilization of ARE-mRNA is enhanced does not mean that ARE-mRNA is transiently stabilized by various stresses, but as described above, for example, in tumor cells. It means a state in which ARE-mRNA can be constantly stabilized in the cell without requiring any stimulus.
- ARE-mRNA stabilization is enhanced is a tumor cell (Lopez et al, Oncogene, 2003, 22: 7146-7154). Therefore, the medicament containing the modified adenovirus of the present invention can be used as an antitumor agent.
- ARE-mRNA stabilization is peripheral mononucleosis and synovial cells (Thiele, et al., Exp. Cell Res., 2006, Vol. 312. No.) in patients with rheumatism. . 12).
- peripheral mononuclear cells of rheumatoid patients the expression of TTP, which promotes the degradation of ARE-mRNA, is significantly reduced compared to that of healthy subjects, while the expression of TNF- ⁇ translated from ARE-mRNA is abnormally increased. It is known that the stabilization of ARE-mRNA is enhanced.
- peripheral mononuclear cells and synovial cells with the modified adenovirus of the present invention, the peripheral mononuclear cells are selectively killed, and the expression of TNF- ⁇ is combined with that of osteoclasts due to inflammation. It is expected that the progression or worsening of rheumatism can be suppressed by suppressing the induction and further suppressing the proliferation of synovial cells that are targets of inflammation.
- the medicine containing the modified adenovirus of the present invention can be used as a medicine for the treatment of rheumatism.
- treatment includes all types of medically acceptable therapeutic interventions aimed at curing or transient remission of a disease. That is, the treatment of a disease involving cells in which the stabilization of mRNA including ARE is enhanced is medically acceptable for various purposes, including delaying or stopping the progression of the disease, regression or disappearance of a lesion, and the like. Including interventions to be performed.
- the present invention provides a medicament containing the modified adenovirus of each of the above-mentioned aspects.
- pharmaceuticals include any other virus, therapeutically effective agents, pharmaceutically acceptable carriers, buffers, excipients, adjuvants, preservatives, fillers, stabilizers, augmentations. It may be in the form of a pharmaceutical composition containing any of the ingredients commonly used in mucilage and / or formulations.
- compositions containing a virus are well known to those skilled in the art, and those skilled in the art can use the ingredients described in the 17th revised Japanese Pharmacopoeia and other standards within the range of normal practicability, depending on the form of the formulation. Can be appropriately selected and used. In addition, it is preferable to use various components used in the preparation containing a virus.
- the medicament of the present invention can be in any form suitable for administration, for example, solid, semi-solid or liquid forms such as solutions, lyophilized powders, emulsions, suspensions, tablets, pellets, capsules, etc. Not limited to these.
- the medicament is used in the form of parenteral formulations such as injections, infusions and the like.
- parenteral formulations such as injections, infusions and the like.
- carriers that can be used in parenteral preparations include aqueous carriers that are usually used in preparations, such as physiological saline and isotonic solutions containing glucose, D-sorbitol, and the like.
- Non-Patent Document 1 a conventional drug containing the oncolytic virus and other viral vectors described in Non-Patent Document 1 (Bischoff et al., Science, 1996, Vol.274, pp.373-376) is produced. It can be manufactured by a method of modifying these or by a method modified by the ordinary ability of a person skilled in the art.
- the medicament of the present invention is administered to pet animals such as dogs and cats, domestic animals such as cows and pigs, and primates such as humans, especially humans.
- Administration of the drug to the subject can be carried out, for example, following a conventional drug containing an oncolytic virus or other viral vector described in Non-Patent Document 1.
- the route of administration will be determined by one of ordinary skill in the art, taking into account the form of the formulation, the disease, the site of the disease and various factors considered when administering the drug.
- the preferred route of administration of the medicament of the present invention is, for example, parenteral administration such as intravascular administration (preferably intravenous administration), intraperitoneal administration, intraperitoneal administration, and local administration into or near a tumor.
- parenteral administration such as intravascular administration (preferably intravenous administration), intraperitoneal administration, intraperitoneal administration, and local administration into or near a tumor.
- the medicament of the present invention is administered to a subject by intravenous administration or topical administration into or near the tumor.
- the administration may be a single administration or a repeated administration.
- the medicament of the present invention is administered in an amount effective for treating a disease which is appropriately determined according to the usage, the age of the subject, the condition of the disease and other conditions.
- the dose range is, for example, 1 ⁇ 10 3 to 1 ⁇ 10 14 per human subject, preferably 1 ⁇ 10 5 to 1 ⁇ 10 12 , More preferably 1 ⁇ 10 6 to 1 ⁇ 10 11 , and most preferably 1 ⁇ 10 7 to 1 ⁇ 10 10 plaque forming units (pfu), once or multiple times a day. It can be administered separately or intermittently.
- the present invention also presents a method of treating a disease involving cells with enhanced ARE-mRNA stabilization, comprising administering to a subject in need thereof an effective amount of the modified adenovirus of each of the above embodiments. Is provided as another aspect.
- the treatment of the disease using the medicine of the present invention is effective alone, but any other treatment, for example, the conventional treatment and the treatment using the medicine of the present invention may be used in combination.
- any other treatment for example, the conventional treatment and the treatment using the medicine of the present invention may be used in combination.
- chemotherapy using other anticancer agents, cancer immunotherapy, radiotherapy, or the like may be used in combination.
- kits were performed according to the kit manufacturer's protocol. It should be noted that the present invention is not limited to the specific methodologies, protocols, cell lines, animal species and genera, constructs and reagents described herein, and these can be changed as appropriate. It is easily understood by those skilled in the art.
- Example 1 1) Preparation of modified adenovirus in which ARE is introduced into the 3'untranslated region of the E1A gene E1 containing the E1A gene and E1B gene of type 5 adenovirus in the Escherichia coli vector pBR322 provided by Dr. T. Shenk of Princeton University.
- the region-inserted plasmid pXhoIC (Logan et al, Cancer Cells 2, 527-532, 1984) was opened with the restriction enzyme HpaI.
- E1A is incorporated with a synthetic double-stranded DNA fragment consisting of a base sequence corresponding to ARE (5'-gtgattattt attatttatt tattatttat ttatttacag-3', SEQ ID NO: 3) contained in the human TNF- ⁇ gene and its complementary strand.
- ARE 5'-gtgattattt attatttatt tattatttat ttattttacag-3', SEQ ID NO: 3
- pXhoIC-ARETNF which is a plasmid containing the E1 region in which the ARE was introduced into the 3'untranslated region of the gene.
- PCR was performed using pXhoIC-ARETNF as a template and a primer set containing a sequence on the cosmid side of 15 base pairs at both ends to prepare an amplified fragment of the E1 region into which ARE was introduced.
- This amplified fragment was incorporated into the SmiI restriction site of pAxcwit2 (Takarabio) containing the adenovirus genome lacking the E1A and E1B genes by the Infusion method, and ARE was introduced into the 3'untranslated region of the E1A gene.
- PAx-ARETNF and pAx-ARETNF-R were constructed as plasmids containing the adenovirus genome.
- the nucleotide sequence of the insert contained in both plasmids is shown in SEQ ID NO: 4.
- pAx-ARETNF holds this insert in the same orientation as the E1A enhancer contained in pAxcwit2
- pAx-ARETNF-R holds this insert in the opposite direction to the E1A enhancer contained in pAxcwit2.
- the 1st to 1217th bases correspond to the E1A gene
- the 1st to 43rd bases are the E1A upstream region containing the TATA box
- the 105th to 1090th bases are the 105th to 1090th bases (partly intron).
- the E1A coding region is the E1A coding region
- the 1091-1217th base is the 3'untranslated region of the E1A gene
- the 1120-1159th base is the introduced human TNF- ⁇ gene-derived ARE.
- the bases at positions 1218 to 2913 correspond to a part of the E1B gene (up to the middle of the coding region of E1B55k).
- the distance between the E1A mRNA start point and the enhancer sequence end in pAx-ARETNF-R is 203 bp
- the distance between the E1A mRNA start point and the enhancer sequence end in pAx-ARETNF-R is 3029 bp.
- a stock of recombinant adenovirus was prepared by infecting 293 cells with chain DNA obtained by cleaving pAx-ARETNF and pAx-ARETNF-R with the restriction enzyme pacI using Hilymax (Dojin Kagaku Kenkyusho). and further using a Fast-Trap adenovirus purification kit (EMD Millpore Co.) to prepare a purified virus (9.0 ⁇ 10 9 viral particle number / mL).
- this virus will be referred to as AdARET and AdARET-R.
- the wild-type type 5 adenovirus wt300 obtained from Dr. T Shenk
- the E1B55k-deficient type 5 adenovirus dl1520 distributed by Dr. A. Berk, University of California
- the cells were infected to prepare a purified virus.
- Example 2 1) Preparation of modified adenovirus in which c-fos-derived ARE was introduced into the 3'untranslated region of the E1A gene pXhoIC was opened with the restriction enzyme HpaI, and ARE (5'-tttt attgtgtttt) contained in the human c-fos gene was opened.
- the ARE was introduced into the 3'untranslated region of the E1A gene by incorporating a synthetic double-stranded DNA fragment consisting of the nucleotide sequence corresponding to taatttatttt attaagatgg attctcagat atttatattt ttattttatt ttttt -3', SEQ ID NO: 6) and its complementary strand.
- a plasmid containing the E1 region, pXhoIC-AREFOS was constructed.
- PCR was performed using pXhoIC-AREFOS as a template and a primer set containing a sequence on the cosmid side of 15 base pairs at both ends to prepare an amplified fragment of the E1 region into which ARE was introduced.
- This amplified fragment was incorporated into the SmiI restriction site of pAxcwit2 by the Infusion method, and pAx-AREFOS and pAx-AREFOS-R were used as plasmids containing the adenovirus genome in which ARE was introduced into the 3'untranslated region of the E1A gene.
- pAx-AREFOS and pAx-AREFOS-R were used as plasmids containing the adenovirus genome in which ARE was introduced into the 3'untranslated region of the E1A gene.
- the nucleotide sequence of the insert contained in both plasmids is shown in SEQ ID NO: 7.
- pAx-AREFOS has this insert in the same orientation as the E1A enhancer contained in pAxcwit2, and pAx-AREFOS-R has this insert in the opposite direction to the E1A enhancer contained in pAxcwit2.
- the 1st to 1246th bases correspond to the E1A gene
- the 1st to 43rd bases are the E1A upstream region containing the TATA box, and the 105th to 1090th bases (partly intron).
- the E1A coding region is the E1A coding region
- the 1091-1246th base is the 3'untranslated region of the E1A gene
- the 1120-1188th base is the introduced human c-fos gene-derived ARE.
- the 1247 to 2942 bases correspond to a part of the E1B gene (up to the middle of the coding region of E1B55k).
- the distance between the E1A mRNA start point and the enhancer sequence end in pAx-AREFOS-R is 203 bp
- the distance between the E1A mRNA start point and the enhancer sequence end in pAx-AREFOS-R is 3058 bp.
- a stock of recombinant adenovirus was prepared by infecting 293 cells with Hilymax with the chain DNA obtained by cleaving pAx-AREFOS and pAx-AREFOS-R with the restriction enzyme pacI, and then Fast-Trap adenovirus.
- Purified virus was prepared using a purification kit. Hereinafter, this virus will be referred to as AdAREF and AdAREF-R.
- Example 3 Antitumor effect of modified virus in cancer-bearing mice transplanted with HeLa S3 cells
- Human cervical cancer-derived HeLa S3 subcutaneously in 5-week-old nude mice (BALB / c nu / nu; female, n 5) Cells (1 x 10 6 ) were transplanted to form a tumor.
- Day 0 was the day when the tumor diameter was confirmed to be 9-10 mm, and the adenovirus dl312 lacking the E1A gene, AdARET-R in Example 1 and AdAREF-R in Example 2 (1 ⁇ 10).
- SEQ ID NO: 1 Nucleotide sequence of modified E4orf6 gene Nucleotide sequence No. 2
- Nucleotide sequence of modified E4orf6 protein Nucleotide sequence No. 3 Nucleotide sequence of ARE of human TNF- ⁇ gene Nucleotide sequence No.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
(2)自己の増殖に必須のウイルス遺伝子がE1A遺伝子である、(1)に記載の改変アデノウイルス。
(3)E1A遺伝子及びE1A遺伝子の発現を増大させる機能を持つエンハンサー配列を有し、かつ正常なE4orf6タンパク質を発現することができない改変アデノウイルスであって、E1A遺伝子5'末端とエンハンサー配列末端との間の距離が1500bp~4500bpである、前記改変アデノウイルス。
(4)改変アデノウイルスが、オンコドメイン内にαヘリックス構造を有するE4orf6タンパク質を発現しないように改変されたアデノウイルスである、(3)に記載の改変アデノウイルス。
(5)配列番号1に示される塩基配列又はこれがコードするアミノ酸配列と同一のアミノ酸配列をコードする塩基配列からなる改変E4orf6遺伝子を有する、(4)に記載の改変アデノウイルス。
(6)配列番号2に示されるアミノ酸配列をコードする改変E4orf6遺伝子を有する、(4)に記載の改変アデノウイルス。
(7)E4orf6を欠失したアデノウイルスである、(4)に記載の改変アデノウイルス。
(8)自己の増殖に必須のウイルス遺伝子の3’非翻訳領域内に又は当該3’非翻訳領域に隣接する位置に導入されたAREを有する、(3)~(7)のいずれか一項に記載の改変アデノウイルス。
(9)自己の増殖に必須のウイルス遺伝子がE1A遺伝子である、(8)に記載の改変アデノウイルス。
(10)(1)~(9)のいずれか一項に記載の改変アデノウイルスを含む、AU-リッチエレメントを含むmRNAの安定化が亢進している細胞が関与する疾患を治療するための医薬。
(11)AU-リッチエレメントを含むmRNAの安定化が亢進している細胞が関与する疾患が悪性腫瘍又はリウマチである、(10)に記載の医薬。
1)E1A遺伝子の3'非翻訳領域にAREが導入された改変アデノウイルスの調製
プリンストン大学、T.Shenk博士より供与された、大腸菌ベクターpBR322に5型アデノウイルスのE1A遺伝子及びE1B遺伝子を含むE1領域が挿入されたプラスミドであるpXhoIC(Logan et al, Cancer Cells 2, 527-532, 1984)を、制限酵素HpaIで開環させた。これに、ヒトTNF-α遺伝子に含まれるARE(5’-gtgattattt attatttatt tattatttat ttatttacag-3'、配列番号3)に相当する塩基配列及びその相補鎖からなる合成二本鎖DNA断片を組み込んで、E1A遺伝子の3'非翻訳領域に前記AREが導入されたE1領域を含むプラスミドであるpXhoIC-ARETNFを構築した。
1×105個のヒト肺胞基底上皮腺癌由来A549細胞株(ATCCから購入)を、2mlのDMEM(10%FBS)を含む6ウェルディシュに接種して、37℃で培養した。培地を除去し、新たに10%FBSを含むDMEMを2ml加え、さらに上記1)で調製したAdARET-RをMOI=1000、wt300又はdl1520をMOI=10となるように加えて、37℃でwt300、dl1520は24時間、AdARET-Rは48時間インキュベーションを行った。培養液からウイルスを回収し、タンパク質を抽出した後、M58抗体を用いたウエスタン法によりE1Aを検出した。その結果、他のウイルスに比べて、AdARET-RのE1A発現量は少ないことが確認された(図1)。
3×103個のヒト正常細胞である包皮皮膚線維芽由来BJ細胞及びヒト子宮頸がん由来HeLa細胞をそれぞれ、100μLのDMEM(10%FBS)を含む96ウェルディシュに接種して、37℃で培養した。培地を除去し、新たに10%FBSを含むDMEMを100μL加え、さらに上記1)で調製したAdARET-RをMOI=10000となるように加えて、37℃でインキュベーションを行った。培養開始から1、5、7日後に、Cell Proliferation kit II(XTT)(Roche社)を用いたXTTアッセイを行って、細胞生存率を測定した。アデノウイルスの代わりに同容量の培地を加えたウェルを対照(mock)とし、mockに対する相対的細胞生存率を算出した。その結果、AdARET-R はHeLa細胞に対して殺細胞活性を示す一方、正常細胞であるBJ細胞には殆ど殺細胞活性を示さないことが確認された(図2)。
上記3)と同様の方法でHeLa細胞及びA549細胞にAdARET-R又はAdARETをMOI = 0.01、0.1又は1となるように加えてインキュベーションを行い、培養開始から7日後のXTTアッセイにより細胞生存率を測定した。その結果、AdARET-R及びAdARETはいずれもがん細胞に対する殺細胞活性を示し、HeLa細胞に対してはAdARET よりもAdARET-Rが、A549細胞に対してはAdARET-RよりもAdARETが、より強い殺細胞活性を示すことが確認された(図3)。
上記3)と同様の方法でBJ細胞にAdARET-R又はAdARETをMOI = 0.01、0.1又は1となるように加えてインキュベーションを行い、培養開始から20日後のXTTアッセイにより細胞生存率を測定した。その結果、AdARET感染細胞よりもAdARET-R感染細胞の方が生存率が高く(図4)、AdARET-Rの方がAdARETよりも正常細胞に対して殺細胞活性が低いことが確認された。
1)E1A遺伝子の3'非翻訳領域にc-fos由来AREが導入された改変アデノウイルスの調製
pXhoICを制限酵素HpaIで開環させ、ヒトc-fos遺伝子に含まれるARE(5’- tttt attgtgtttt taatttattt attaagatgg attctcagat atttatattt ttattttatt ttttt -3’、配列番号6)に相当する塩基配列及びその相補鎖からなる合成二本鎖DNA断片を組み込んで、E1A遺伝子の3'非翻訳領域に前記AREが導入されたE1領域を含むプラスミドであるpXhoIC-AREFOSを構築した。
1×105個のA549細胞株を、2mlのDMEM(10%FBS)を含む6ウェルディシュに接種して、37℃で培養した。培地を除去し、新たに10%FBSを含むDMEMを2ml加え、さらに上記1)で調製したAdAREF又はAdAREF-RをMOI=10となるように加えて、37℃で72時間インキュベーションを行った。培養液からmRNAを回収し、E1A primer(Fw: 5’-GAACCACCTACCCTTCACG-3’(配列番号8)、Rev 5’-CCGCCAACATTACAGAGTCG-3(配列番号9))を用いた定量性real-time RT-PCR法により、E1A mRNAの定量を行った。その結果、AdAREFに比べて、AdAREF-RのE1A mRNA発現量が少ないことが確認された(図5)。
5×104個のHeLa細胞株、A549細胞株及びBJ細胞株を2mlのDMEM(10%FBS)を含む6ウェルディシュに接種して、37℃で培養した。培地を除去し、新たに10%FBSを含むDMEMを2ml加え、さらに上記1)で調製したAdAREF又はAdAREF-RをMOI=10となるように加えて、37℃で72時間インキュベーションを行った。インキュベーション後に培地からウイルスを回収し、Adeno-X(登録商標) Rapid Titer Kit(Clontech)によってウイルス外殻構成タンパクのヘクソンを293細胞を用いて染色することにより、ウイルス量を測定した。その結果、AdAREFに比べて、AdAREF-Rの方が正常細胞における増殖能が低いことが確認された(図6)。
5週齢のヌードマウス(BALB/c nu/nu;雌、n=5)の皮下にヒト子宮頸がん由来HeLa S3細胞(1×106個)を移植し、腫瘍を形成させた。腫瘍の直径が9-10 mmになったことを確認した日をDay 0として、E1A遺伝子を欠失したアデノウイルスdl312、実施例1のAdARET-R及び実施例2のAdAREF-R(1×109 vp; 100μl)を計2回(Day 1とDay 4)各腫瘍に直接投与し、腫瘍の体積(mm3、長径×短径2×0.5により算出)を経時的に測定した。腫瘍体積の測定は、Day 0から5日おきに行った。その結果、AdAREF-R、AdARET-Rを投与した群では共に腫瘍の増大が抑制され、両ウイルスのin vivoでの効果が確認された(図7)。
配列番号2 改変E4orf6タンパク質のアミノ酸配列
配列番号3 ヒトTNF-α遺伝子のAREの塩基配列
配列番号4 pAx-ARETNF及びpAx-ARETNF-Rのインサートの塩基配列
配列番号5 5型アデノウイルスE1A遺伝子のエンハンサーの塩基配列
配列番号6 ヒトc-fos遺伝子のAREの塩基配列
配列番号7 pAx-AREFOS及びpAx-AREFOS-Rのインサートの塩基配列
配列番号8 5型アデノウイルスE1A遺伝子を増幅するためのフォワードプライマー
配列番号9 5型アデノウイルスE1A遺伝子を増幅するためのリバースプライマー
Claims (11)
- E1A遺伝子、E1A遺伝子の発現を増大させる機能を持つエンハンサー配列、及び自己の増殖に必須のウイルス遺伝子の3'非翻訳領域内に又は当該3'非翻訳領域に隣接する位置に導入されたAU-リッチエレメントを有する改変アデノウイルスであって、E1A遺伝子5'末端とエンハンサー配列末端との間の距離が1500bp~4500bpである、前記改変アデノウイルス。
- 自己の増殖に必須のウイルス遺伝子がE1A遺伝子である、請求項1に記載の改変アデノウイルス。
- E1A遺伝子及びE1A遺伝子の発現を増大させる機能を持つエンハンサー配列を有し、かつ正常なE4orf6タンパク質を発現することができない改変アデノウイルスであって、E1A遺伝子5'末端とエンハンサー配列末端との間の距離が1500bp~4500bpである、前記改変アデノウイルス。
- 改変アデノウイルスが、オンコドメイン内にαヘリックス構造を有するE4orf6タンパク質を発現しないように改変されたアデノウイルスである、請求項3に記載の改変アデノウイルス。
- 配列番号1に示される塩基配列又はこれがコードするアミノ酸配列と同一のアミノ酸配列をコードする塩基配列からなる改変E4orf6遺伝子を有する、請求項4に記載の改変アデノウイルス。
- 配列番号2に示されるアミノ酸配列をコードする改変E4orf6遺伝子を有する、請求項4に記載の改変アデノウイルス。
- E4orf6を欠失したアデノウイルスである、請求項4に記載の改変アデノウイルス。
- 自己の増殖に必須のウイルス遺伝子の3’非翻訳領域内に又は当該3’非翻訳領域に隣接する位置に導入されたAREを有する、請求項3~7のいずれか一項に記載の改変アデノウイルス。
- 自己の増殖に必須のウイルス遺伝子がE1A遺伝子である、請求項8に記載の改変アデノウイルス。
- 請求項1~9のいずれか一項に記載の改変アデノウイルスを含む、AU-リッチエレメントを含むmRNAの安定化が亢進している細胞が関与する疾患を治療するための医薬。
- AU-リッチエレメントを含むmRNAの安定化が亢進している細胞が関与する疾患が悪性腫瘍又はリウマチである、請求項10に記載の医薬。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021507412A JP7406263B2 (ja) | 2019-03-20 | 2020-03-19 | 改変アデノウイルス及びこれを含む医薬 |
EP20774238.8A EP3943113A4 (en) | 2019-03-20 | 2020-03-19 | MODIFIED ADENOVIRUS AND MEDICATION COMPRISING IT |
CA3135295A CA3135295A1 (en) | 2019-03-20 | 2020-03-19 | Modified adenovirus and medicine comprising same |
US17/439,184 US20220152133A1 (en) | 2019-03-20 | 2020-03-19 | Modified adenovirus and medicine comprising same |
CN202080021634.9A CN113573741A (zh) | 2019-03-20 | 2020-03-19 | 修饰腺病毒和含有其的医药 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019-053895 | 2019-03-20 | ||
JP2019053895 | 2019-03-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020189749A1 true WO2020189749A1 (ja) | 2020-09-24 |
Family
ID=72520204
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2020/012196 WO2020189749A1 (ja) | 2019-03-20 | 2020-03-19 | 改変アデノウイルス及びこれを含む医薬 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20220152133A1 (ja) |
EP (1) | EP3943113A4 (ja) |
JP (1) | JP7406263B2 (ja) |
CN (1) | CN113573741A (ja) |
CA (1) | CA3135295A1 (ja) |
TW (1) | TWI819203B (ja) |
WO (1) | WO2020189749A1 (ja) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016160249A (ja) | 2015-03-05 | 2016-09-05 | 国立大学法人北海道大学 | 腫瘍溶解改変アデノウイルス、疾患治療用改変ウイルス及びこれらを含むウイルス製剤 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6900049B2 (en) * | 1998-09-10 | 2005-05-31 | Cell Genesys, Inc. | Adenovirus vectors containing cell status-specific response elements and methods of use thereof |
US9017672B2 (en) * | 2012-05-11 | 2015-04-28 | Immunicum Aktiebolag | Hexon Tat-PTD modified adenovirus and uses thereof |
-
2020
- 2020-03-19 US US17/439,184 patent/US20220152133A1/en active Pending
- 2020-03-19 EP EP20774238.8A patent/EP3943113A4/en active Pending
- 2020-03-19 JP JP2021507412A patent/JP7406263B2/ja active Active
- 2020-03-19 CA CA3135295A patent/CA3135295A1/en active Pending
- 2020-03-19 TW TW109109287A patent/TWI819203B/zh active
- 2020-03-19 WO PCT/JP2020/012196 patent/WO2020189749A1/ja active Search and Examination
- 2020-03-19 CN CN202080021634.9A patent/CN113573741A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016160249A (ja) | 2015-03-05 | 2016-09-05 | 国立大学法人北海道大学 | 腫瘍溶解改変アデノウイルス、疾患治療用改変ウイルス及びこれらを含むウイルス製剤 |
Non-Patent Citations (11)
Title |
---|
BISCHOFF ET AL., SCIENCE, vol. 274, 1996, pages 373 - 376 |
ELOIT M. ET AL.: "Isogenic adenoviruses type 5 expressing or not expressing the E1A gene : efficiency as virus vectors in the vaccination of permissive and non-permissive species", JOURNAL OF GENERAL VIROLOGY, vol. 76, 1995, pages 1583 - 1589, XP002028963 * |
HALBERT D. N. ET AL.: "Adenovirus early region 4 encodes functions required for efficient DNA replication, late gene expression, and host cell shutoff", JOURNAL OF VIROLOGY, vol. 56, no. 1, 1985, pages 250 - 257, XP001000467 * |
HALBERT ET AL., J. VIROLOGY, vol. 56, 1985, pages 250 - 257 |
HEARING P. ET AL.: "The adenovirus type 5 E1A enhancer contains two functionally distinct domains: one is specific for E1A and the other modulates all early units in cis", CELL, vol. 45, 1986, pages 229 - 236, XP024244018, DOI: 10.1016/0092-8674(86)90387-9 * |
HIGASHINO ET AL., J. CELL BIOL., vol. 170, 2005, pages 15 - 20 |
LOGAN ET AL., CANCER CELLS, vol. 2, 1984, pages 527 - 532 |
LOPEZ ET AL., ONCOGENE, vol. 22, 2003, pages 7146 - 7154 |
MIKAWA YOHEI, TOWFIK ALAM MOHAMMAD, HOSSAIN ELORA, YANAGAWA-MATSUDA AYA, KITAMURA TETSUYA, YASUDA MOTOAKI, HABIBA UMMA, AHMED ISHR: "Conditionally replicative adenovirus controlled by the stabilization system of AU -rich elements containing mRNA", CANCERS, vol. 12, no. 5, 1205, 11 May 2020 (2020-05-11), pages 1 - 13, XP055851593, DOI: 10.3390/cancers12051205 * |
See also references of EP3943113A4 |
THIELE ET AL., EXP. CELL RES., vol. 312, no. 12, 2006 |
Also Published As
Publication number | Publication date |
---|---|
EP3943113A1 (en) | 2022-01-26 |
US20220152133A1 (en) | 2022-05-19 |
CA3135295A1 (en) | 2020-09-24 |
JPWO2020189749A1 (ja) | 2020-09-24 |
CN113573741A (zh) | 2021-10-29 |
EP3943113A4 (en) | 2023-05-10 |
JP7406263B2 (ja) | 2023-12-27 |
TW202102677A (zh) | 2021-01-16 |
TWI819203B (zh) | 2023-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101878274B1 (ko) | 암 치료용 암 용해성 아데노바이러스 | |
JP6639412B2 (ja) | アルブミン結合部分を含んでなるアデノウイルス | |
JP3875990B2 (ja) | 組換えアデノウイルスベクターおよび使用方法 | |
FI118011B (fi) | Menetelmä replikaatiokyvyn suhteen puutteellisen yhdistelmä-DNA-adenoviruksen tuottamiseksi | |
JP2022023074A (ja) | 腫瘍選択的e1aおよびe1b変異体 | |
US20100151576A1 (en) | Targeted tumor therapy by use of recombinant adenovirus vectors that selectively replicate in hypoxic regions of tumors | |
Zhu et al. | Oncolytic adenovirus armed with IL-24 inhibits the growth of breast cancer in vitro and in vivo | |
JPH06508039A (ja) | 抗腫瘍治療のためのサイトカインを発現する組換え型欠損アデノウイルス | |
EP1553178B1 (en) | Oncolytic virus growing selectively in tumor cells | |
Liu et al. | Strategy of Cancer Targeting Gene-Viro-Therapy (CTGVT) a trend in both cancer gene therapy and cancer virotherapy | |
WO2003006640A1 (fr) | Virus a proliferation specifique dans les cellules tumorales, qui peut exprimer un antioncogene avec une grande efficacite, et utilisation de ce virus | |
WO2020189749A1 (ja) | 改変アデノウイルス及びこれを含む医薬 | |
JP2022512903A (ja) | Ad-REIC/Dkk-3とチェックポイント阻害剤とを用いた胸部がんの治療のための併用療法 | |
JP4431091B2 (ja) | 組換えアデノウイルスベクターおよび使用方法 | |
JP2016160249A (ja) | 腫瘍溶解改変アデノウイルス、疾患治療用改変ウイルス及びこれらを含むウイルス製剤 | |
US11951141B2 (en) | Replication-enhanced oncolytic adenoviruses | |
US20090175825A1 (en) | Interferon alpha and antisense k-ras rna combination gene therapy | |
WO2021020554A1 (ja) | REIC/Dkk-3遺伝子と抗腫瘍剤との併用による肝臓がんの治療方法 | |
WO2022170919A1 (zh) | 一种重组溶瘤腺病毒及其应用 | |
JP2007528715A (ja) | 新規アデノウイルスを用いた癌治療方法及び組成物 | |
AU2022223330A1 (en) | Viral delivery of a sialidase to treat cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20774238 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2021507412 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 3135295 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2020774238 Country of ref document: EP Effective date: 20211020 |